StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $19.93 | $19.33 | -3.01% | 0.1M |
| 05-11 | $18.91 | $19.20 | +1.53% | 0.1M |
| 05-12 | $19.07 | $19.25 | +0.94% | 0.1M |
| 05-13 | $19.10 | $19.24 | +0.73% | 0.0M |
| 05-14 | $19.25 | $19.02 | -1.19% | 0.0M |
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Each factor shows LYEL's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
No sell-side coverage available for LYEL.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for LYEL.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $4.69K | $2.00K | $36.00K | $30.00K | $15.00K |
Operating Income | Not available | $-44.26M | $-269.40M | $-141.76M | $-104.51M |
Net Income | Not available | $-24.15M | $-274.45M | $-133.72M | $-94.88M |
EPS (Diluted) | $-2.40 | $-1.10 | $-16.06 | $-8.38 | $-6.42 |
Total Assets | Not available | $350.63M | $340.05M | $407.96M | $385.45M |
Total Liabilities | Not available | $76.96M | $91.85M | $78.84M | $86.53M |
Cash & Equivalents | Not available | $90.77M | $60.18M | $123.58M | $98.80M |
Free Cash Flow OCF − CapEx | Not available | $-38.60M | $-150.80M | $-118.25M | $-89.61M |
Shares Outstanding | Not available | 23.33M | 21.25M | 19.29M | 14.83M |
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.